T-cell receptor alpha chain (TRA) (TRA)

The T-cell receptor alpha chain is a vital protein component that heterodimerizes with the TCR beta chain to form the alpha-beta T-cell receptor (TCR) complex, which is expressed on the surface of the majority of T lymphocytes [UniProt: P01848]. This receptor complex is responsible for recognizing specific antigenic peptides presented by Major Histocompatibility Complex (MHC) molecules, a process that is fundamental to the initiation of the adaptive immune response [PMID: 25607114]. In therapeutic applications, the TCR alpha chain is a primary target for genetic engineering in TCR-T cell therapies, such as Afamitresgene autoleucel, which are designed to redirect T-cells toward specific cancer antigens like MAGE-A4 [FDA: Tecelra]. Additionally, the genetic disruption of the TCR alpha constant (TRAC) locus is a key strategy in developing allogeneic CAR-T therapies to eliminate endogenous TCR expression and thereby prevent graft-versus-host disease [PMID: 28249977]. Beyond oncology, the TCR complex is targeted by immunosuppressive agents to treat autoimmune disorders and prevent transplant rejection by modulating T-cell activation pathways.

Other names

TCR alphaTCRAT-cell receptor alpha locusTRACT-cell receptor alpha constant

TCR-engineered T-cell therapy involves the recombinant expression of specific TCR alpha and beta chains to target tumor antigens [PMID: 31142852]. Monoclonal antibodies target the TCR/CD3 complex to modulate T-cell signaling [PMID: 25607114]. CRISPR-mediated knockout of the T-cell receptor alpha constant (TRAC) region is used to prevent graft-versus-host disease in allogeneic CAR-T cells [PMID: 28249977].